DARE - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the conference call hosted by Daré Bioscience to review the company's first quarter financial results and to provide the general business update. This call is being recorded. My name is Alex, and I will be your operator for today.

With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer. Ms. proceed. please Johnson,

Sabrina Johnson

results afternoon, Results Good ended to Daré portfolio. first the XX, from and Thank pipeline our Business and Update Financial and quarter our review and Today, quarter discuss Call Bioscience developments XXXX. expectations you. we'll welcome and for March the

statements historical made Securities due statements I of could or forward-looking to the results Reform during statements this will laws, anticipated call federal that uncertainties. these Litigation forward-looking events facts statements. would which to you the are not known or the differ within of Any those statements by considered are discussion to materially today's remind pursuant and from should safe securities unknown provisions be harbor the implied Private like and made Actual risks XXXX. of that include meaning Act of

undue statements. You on should reliance not place forward-looking

content for May company's the XX, in Forward-looking including would our statements cautionary today. that filed to the are also XX-Q statements of quarter reflect undertakes by I qualified developments like XXXX. their point law. filings, this includes this obligation SEC is statements no XX, forward-looking update call, which to any Daré as entirety new as was of information the information required out by ended the in Form XXXX, current to that only call or except today, after time-sensitive March

a those Daré today's minute believe for purpose health Before through you remind to broadly, only mission. on our product like and Daré advancing well-being may solely regulatory pharmaceutical disruptive and clinical focused take the to publicly review development, development to to company women and ultimately we and begin is market. the we traded be of health, of story update, remain to dedicated I'd the products who of newer We women's

seek need active improve leveraging pharmacology pharmaceutical the is understood and of basic health certain Our gaps. is target is the the address not effect treatments to about that our existing products suited accelerate women. for that boldly indication the applied been marketed commitment pharmacology outcomes to lives and profile want addressing that for science to and We outcomes treatments innovative and to previously therapeutic has indication by and and enhance optimize side or ingredients focus and where to well women by a convenience these novel indications question women to

product proof We the and us positions already well have and first-in-category pipeline the long medium candidates, broadest robust have potential our we believe short, for of of portfolio term. demonstrated assembled which of high-impact concept many that

our anticipated milestones discussed results On we recent strides update we for women and and XXXX. the to full made innovative year financial last advance XXXX year call, for therapies the key

vaginal FDA-approved by XACIATO, treatment for vaginosis phosphate today, older So and Organon commercialization by gel available aged the to product prescription XX addition in of from our bacterial emerge portfolio in nationwide. that's X%, our clindamycin the to first now collaborator, continued and a female

clinical trial III Phase first-in-category continued hormone-free, candidate. candidates III enrollment Sildenafil study X.X% intravaginal of sexual treatments, FDA-approved toward On milestones of that we arousal discussed and disorder, on Ovaprene, XXXX potentially in last product a there anticipated female relating are contraceptive for first-in-category focused Cream our our in to progress which our no Phase call, monthly

to Cream. that review III and are shareholders, against recent context with candidates, providing focus ago. strategic our important quarter and weeks of accomplishments announced a Sildenafil Ovaprene royalty progress metrics the milestones, million highlights, XXXX as we're we including first a anticipated as also Phase going financing our our well on nondiluted the cover to important Today, $XX current We'll future XXXX the and some couple

to to do, going review Accounting MarDee, our to financial Officer, it results. over I Chief quarter turn first I'm our Before first

MarDee Haring-Layton

us joining will now first Daré's for everyone, XX, to like refer results to I quarter. March the as thanks, today. and XXXX, financial quarter which Sabrina, summarize I ended the for would Thanks,

meaningful mentioned, women's product our and the to we've Daré's address differentiated Sabrina identified near clinical needs business portfolio's over As strategy term. is monetize unmet health regulatory a portfolio then assemble to advance in advances the value that and candidates long and of and of

The required or and acquisition overhead a to investment and maintenance and advance development corporate build portfolio expenses. costs research and R&D portfolio includes ongoing

the XXXX, and administrative approximately million. expenses our of general quarter During first were $X.X

a clinical, to is period first manufacturing, our the to which across and from regulatory decrease quarter, R&D R&D portfolio million expenses, Our period XXXX. entire were compared on QX activities for other preclinical, which XX% $X.X vary based approximately

be clinical to the related to in expect other costs case to a lower quarters. future Cream we expenses we clinical future III quarters expenses, R&D be XXXX Until commence Closeout the study, and for not in Phase Sildenafil and quarter first R&D first expenses. Cream quarter clinical R&D than significantly study the contributed conducted will RESPOND Sildenafil Phase our of which IIb studies

for ended was loss $X.X million. the quarter Our of had XXX of cash cash first comprehensive approximately shares million million stock XX. equivalents May common We $X.X approximately with as and the quarter and approximately in outstanding

of to a with The transaction and Ovaprene and announced and upside sharing achieve of which Daré allows margins sales the future first-in-category attractive net all all commercial through XOMA XACIATO to have the transaction. structure proceeds in and flows Sildenafil underscores XOMA, payments focus economics to success future XOMA our under and on Daré ability XX% of represent This in of large achieve which recently ensures Phase opportunities. gross capital in progresses. This significance monetization market shareholders to Daré from the following commercial prespecified importantly, the flows of Cream that and $XX also this a million royalty milestone will Ovaprene help opportunity both accelerates total to XOMA Cream, future transaction and retained our us significant milestones. with We of to commercialization III received investigational Sildenafil equal advancing and royalty products, net monetization objectives remaining payments meaningfully to nondilutive provides economics milestone as net return XACIATO cash financing and participate to our the sold cash potential make

In to $X.X under received nonclinical to seeking to agreements product Together, We relating commitment under agreement. approximately the application DARE-LARCX of we grant April opportunistic and encourage on Daré as to approximately of the the our to financials, on a collaborative contraceptive turn the the proof XXXX, the which to ended million Daré in to funding XX-Q for detailed in more financing FDA, report represent our we Sabrina. annual Form our in creative, review date, activities $XX total in of the advance testing humans. To XX, in in agreement submission with and related development. of liquidity, DARE-LARCX other over royalty principle filed of grant $XX.X new our addition and grant with investigational XX, report installment to required call fund resources the capital as XXXX. I XX-K this which grant approximately back condition, to our December has million of bacteria-based March our may which in XXXX, to being XX, biotherapeutic and quarter support of ended prepare funding well drug through financing, foundation shareholder objectives meet work Risk January Form total to of approval for year up and this receive latest and live million to studies Factors investors our received an on now investigational needed to DARE-LARCX discussion the development under for begin grant is DARE-LARCX was our like value. capital build March filed to our afternoon financial and the quarterly would

Sabrina Johnson

accomplishments some focus now first on assets, anticipated XXXX quarter going Ovaprene. through Phase Sildenafil XXXX Thank Cream MarDee. our and a milestones talk you, I'm and III our to with

phosphate update first, assets, our gel or provide The XACIATO. just clindamycin an I'll X%, vaginal on-market on XACIATO

reminder, place. indicated be goal XACIATO time XX the gel can at for as colorless, treatment single-dose time is of retention in years a in and time vaginal limiting and of It's that increasing females day. it's applied spent and bacterial age the formulated of with vaginosis known a leakage older. of any vaginal As

XACIATO the with The of Women's from continues of move we clinicians ramp-up prescription Organon tried progressive by with continues targets their from trial This patients practice. who as year multiple of XACIATO acceptance In health strong of commercialization in have their available first key provider build see full quarter our launch. Organon, team to first momentum the care States. uses XXXX, United through agreement sales to Health across through became the

talk Sildenafil now I'll Cream, about X.X%.

also treatment sexual Sildenafil we completion quarter, the Phase FDA Cream female first on of announced meeting a the the II end arousal disorder. an of for successful the of development with as During

are there Sildenafil FDA-approved potential, potential any in meaning of has Cream arousal sexual of In for and revenue terms market disorder be to no treatments the first. the currently women, form

sexual in for XX the men, was of research form women ever ingredient oral no dysfunction active under currently that launched. arousal. treatment the undoubtedly tablet in low is administration for brand million of prescription Viagra products Market erectile symptoms one the most United name which or of the successful the suggests Sildenafil approximately marketed States in experience

Cream.. to both end RESPOND clinical statistically demonstrated full FDA Sildenafil identified Cream analyses The the probability clinical from we've all call, of study points and study we III the also were quantitative most analyses data completed patient those data in of significant year success, flow meaningful the shared results study IIb of within increased for and during Sildenafil And propose post-hoc already Sildenafil exploratory the in XXXX IIb terms tissue studies. Phase patient our were that Phase population improvement. demonstrated blood of recently Cream showed as IIb Phase the In and we Phase that genital development study of

candidate continuing of feedback Phase first are III on pivotal feedback for development. as on disorder reviews III the agency the therapeutic design proposed FDA our women. collaboration be treatment updates Phase and relevant well the as arousal any We quarter the study providing We generated providing plans the has to the this Phase study take Phase interact it in anticipates forward during the III FDA second look the updates specifically design, as year. to on of this data indicated ever as available would The III FDA's that a strategy forward on additional into to which endpoints with

now Ovaprene. And to

update a which intravaginal an Nonhormonal Ovaprene, provide approved Bayer. monthly a license to U.S. commercial Phase are contraceptive by our III significant currently rights are and of agreement want monthly opportunity, study contraceptive, is hormone-free whose the on contraception hormone-free novel FDA. market no represents also the investigational with there commercial We under

in candidates women important products control on or category birth U.S. use the prefer for Ovaprene or potential a in option commenced at XXXX. Ovaprene. research, and has hormone-based to patient approximately XX for market the be women million of so. and Working of an enrollment in we contraceptive Institute product the disruptive National not potential the Based in with or NICHD Ovaprene pivotal Shriver the who cannot Eunice do Child the National are to Kennedy Development collaborators December of Health Health study study clinical Human III Phase Institute NIH,

Recruitment year. the that is XX study supported at advertising by currently the March is a launched across for and United this States underway in campaign sites central of

link of completion, in and provide which relevant hormone-free campaign coming they updates visiting campaign join study launched We page. revolution call a to responded also if were plan any recruitment checking use qualified the as the quarters. product the updates study. immediately our many to enrollment website months find We can You progresses how March see provide home we to will thrilled for in data by materials our to the by women anticipated in when on to in the involves to XX participate timing

a And announced date the And application be precisely designed if that proof-of-concept registration the the therapeutic for over and drug communications deliver through months Based is implanted in earlier, our for first technological talking FDA. that to importantly, years drug platform, will with required was to to a preclinical we on believe MarDee submission of premarket quarter the with or we its study we doses that just achieved delivery single about support successful, which candidates device. store FDA, innovative DARE-LARCX. single approval underlying lastly,

injections. health but This delivery women's requires health, frequent or where as regular the conditions outside milestone dosing well potential only reflects platforms drug transformative treatment of as various not in women's

conditions reversible are drug implant, We a delivery reversible which this the to solution of flexibility drug as we platform the the long-acting this technology the methods. But transform shorter-acting long-acting to chronic contraceptive user-controlled, well. see utilizes proprietary delivery designed for DARE-LARCX other platform combine as with treatment developing potential benefits certain contraceptives of of

begin precisely to conditions conditions active and a excited duration prolonged longer this patients. other diabetes, requiring discussions potential to to we milestone, as and the precise with with So chronic platform's working over strategic pharmaceutical array for wide address burden with lower are of treatment, leveraging pharmaceutical obesity companies ingredients deliver such a

of mentioned providing other product an as candidates, current MarDee DARE-LARCX relevant as grant. look supported and and the foundation our by our DARE-LARCX earlier, And year. implant is programs updates million and development up other this to enhanced $XX relevant ongoing they technology DARE-LARCX forward portfolio, grant-funded grant funded on to we

to treatments in for many women and collaborating for Bayer summary, and looking to XACIATO to potentially for as in of the we're well-being as excited of updates we women health and disruptive progress including companies, possible. leading these forward So Organon candidates Ovaprene commercialize year decades more as deliver work this with advance are to made about providing the we've some and most

I'd for Q&A. the turn over like So to operator now to call the

Operator

[Operator Wainwright. Tsao comes from Instructions] Douglas with the of question your line first And H.C.

Douglas Tsao

now needed that I to on I initiate additional from some you're Sildenafil III? the of just maybe walk Phase mean you Sabrina, through would guess, Cream. looking feedback be some for help us that steps can FDA

Sabrina Johnson

thanks. Doug, Yes, question. Great

we as to like on feedback and do important make some we're we're endpoint what a so can trying But all up endpoints all other design everything that sure make things And can we're are and sure final that. to trial are III that activities we to hierarchy make your sure that for so for Phase waiting I we're ready. that of lined the that the of yes, that. So mentioned, question, doing clinical we to is required start the

your we and sites use. things place, and materials activities budget having sure So to have we those line these include into that such clear in selecting sight right, of as CRO, your a want study making

to sure continue, placebo the supplies, that test the study, we had experience the who helpful used materials, but that of Phase that's clinical we trial. we're of terms making so study we're ready IIb just the sure selecting III want with Phase because obviously, in making to and product know Now that from sites ready the in we right, and regard, in investigational

that proceed, we those as underway we to quickly activity So earlier are that activities are the that make as year, soon and we started are get well that really and frankly, to underway the quite some that FDA gating to right, this we the not ready some move isn't -- from feedback yet as had that other reasonable are other as and there completed. sure

Douglas Tsao

just helpful. timing Okay. maybe we Great. And when help about understand should data a That's start on then final initial of from of standpoint? just getting us or maybe sort readout a sort think just Ovaprene, to

Sabrina Johnson

Yes. Great question.

XXX the the around XXX, to meaning months may So familiar a the we'd is to be the with trial, in use product. have women over trial, not for to study, goal XX-month who the follow like Ovaprene is the subjects And complete them them use of to XX study, months. course those our XX of have

I went express aware started enrolling like happy and mentioned, of like, -- last is with then to this, platforms at are year. them my to you of as people comments, we are responsiveness live as we subjects to leverages the in imagine, in to as can advertisement make much the their advertising I which important sites. sure campaign, out and which can started so we the how mentioned the campaign, social matches the reach media saw really definitely study studies interest in end very And And we March. And it

want do lines, having about we perspective the for single ad open-label and going in happy seeing bit give all that that your important campaign. been that, So because the it's to and has the to guidance, little campaign And some on an lines time are is question reason Ovaprene. with with the we study, the specific that. But everyone live and everyone give going us all to time on advertising which is to the arm, going very this responsiveness meaning and very do of is expect we're March, when important is is they're campaign advertising early just a we said how

And into opportunity to final the an sight line data gives how having look so when there's data and that will going at to a opportunity interim is an and happen when us understand obviously, of will come. if enrollment

this data certainly hope line So at of what that final point, updates we to would meaningful the with until have patient able -- definitively, get start can we That further live this ad that this I better the feasible we give anticipate some given bit when study. year. share have given is the that we be the And can anticipate little time expect enrollment when we say last campaign, as But we recruiting to we wouldn't end we didn't definitely with really of guidance exactly year. a to to as then be we'll year last the don't out.

Operator

Brookline of question Dolliver comes Capital Markets. from next the line with Your Kemp

Brian Kemp Dolliver

you down, the based readout see to on the want spending trial. step questions the plans time, and theory, Ovaprene your at your a the balancing you some XX and have we'll for months a language much now between ask current in that obligation runway. -- I the an in could current But your really to fact pretty the regarding levels there's cash get possibly and your you sober remaining likely R&D don't because small funding couple regarding past expense of have same XX-Q Ovaprene the the act that's

place? And we XOMA you're the to readouts with -- the the with spending? in should about with how able think get So financing where the particularly

Sabrina Johnson

question. Great you. Thank Yes.

a as and we study. And noted, we noted, nature MarDee the prepared to at spend, our until And start Phase we what of so we our Doug's of Ovaprene today, question, at already III NIH around a in noted, point, be lot least on left right, spending based spend want a R&D research Sildenafil to trial under There's to Sildenafil we've as this reduced funds $XXX,XXX because we and to already response the can as on on until mentioned compared we arrangement But a payment know million. that. and that Phase that comments as agreement, collaborative the last to there's otherwise, had on III you that. significantly as was as committed the year the remitted it's in MarDee you R&D not her on study, is start mentioning I expectations move quickly to $XX the single another

when look our you last consideration that just $XX absolutely When at call, million was all had taking burn, of in million you start So expected our year that into $XX MarDee, with provided the guidance which baseline year, this G&A just some right? we, our impactful. about for is

n to in potentially of us in but a but of million. is what terms to about point, some to the And sure gets to very point, goes clear being enrollment is clear, the timing Viagra very Sildenafil progressing really your that think $XX a our dollar the single want in no, we the some communication In in relation make like how to potential things, further lot we of look be when is milestones that of $XX even given that our amount than interim communication your on Ovaprene, right, million. trial important do we're at want to to data even marketplace, scheme you that, opportunities depending and that

Brian Kemp Dolliver

to to now you're That's initiation? that include the be million does And very $XX engaged prior activities in helpful. clear,

Sabrina Johnson

startup we all-in cost right, the because manufacturing for right number does like activities, it's $XX what trials clinical the the the does startup certain expect be. things include manufacturing, to product It site million the of

Brian Kemp Dolliver

and maybe you can from the the the assuming is reasonable, there along it surprising you Because hiccups is but are a start -- reasonable early FDA only XXXX when do with And preparation, in is way initiating Okay. like looks not feedback minor or XXXX? that early expectation trial? when

Sabrina Johnson

we've check a protocol hope. our make a and just contract as being great do quickly to it, to the There's protocol That's we're and to Yes, we the then way at sure Like final all You once move until the boxes can't can that's that able as activities, have sites. checked that we can we got trying all that right? we we right? there's look have final protocol. with have but to start-up things definitely

fast to That's possibly intent objective. So is That's as our can. move our we our goal. as

definitely, And so to we comments predicated a to is can we're point, clear. do getting hopefully, up every that the of FDA. back said we have that move very position make love so as But that this to the we're you they're so it from in like And timing on be year. to front, off quickly. But activity sprint. that ticked noted, trying we other to I sure ready your

Brian Kemp Dolliver

delay Okay. have the say, certainty to around you have, flexibility And you until runway? trial the your initiating more

Sabrina Johnson

right, right? so things at that Absolutely. choice, XXX% to It's all discretion. are activities our but the we're control, in at within go expenses, significant in So completely ready they're important our not doing our of that timing terms are now we

Operator

Your next Research. of Catherine Novack Jones the line comes with from question

Catherine Novack

Good afternoon.

trial, and that Just study still We on are the Phase Can previously you feedback. aligned population. waiting one remind the were regard what you on indication potential us to you with know trial. III on another Sildenafil

then potentially longer would study? Or shorter? or are you And timing, What's So it the proposing? are a what endpoints you is the XX-week duration? this be --

Sabrina Johnson

the from to where the we based FDA FDA we question Phase the information III kind, clarity of reminder Great needs little the reasonably Yes. have December first our everyone we this great go refresh meeting more its already all through of that really, a time and provided. feel given great is sort and of on where to study where on

question. to your So

been of and duration population the have FDA. period, with statement patient the of the importantly, So agreed and indication efficacy first the all, all the

arousal disorder, right, the a have That's desire. arousal patient sexual female straightforward. It's a dysfunction. disorder not female disorder, common arousal a sexual very including statement common. as decrease women indication happens who only The treatment in of very is rectal may the as arousal in thing So result, female population that disorder. in same are their It's sexual with women

a So to erasable decrease very desire. to dysfunction in common lead for an

had So patient is the conditions the be meeting just our XX-week includes product for suggest and disorder in FDA study this it terms of much but arousal there would nature, II in But studies that with was of for may our our the of that an guidance efficacy women with events of population. And frankly, in the of based that's in comfortable few and be sexual FDA you XX-week different number period the data Phase can dysfunctions study then a duration a ability the XX-week FDA to on terms end show how in sufficient. of a actually assessment, document adequately necessary III. efficacy experiences Phase capture powered that sexual

questions funding, right, safety necessary a and a for to right we've to in of are things outstanding get those what also by much we're really Where a duration exposure that's areas. have the understanding so just product. of terms tells able because places got in of still the part that why like on prepped terms lot where clarity. of ultimately data -- that does, way, good you some now One And couple is the may So needed. lot us in be are support we or give that it

right? partners, partners, safety we that. exposure study instance, data included see We for the Phase XX-week in have So our from to IIb to

that regard. And expectations second, to that clearly we endpoint. then make to on any So make clearly sure aligned aligned we're we're in we want on the sure want

we And so your question around what so suggested. have was

endpoint co-primary We questionnaire function the genital So just part sensation reminder, Phase questions questionnaire. a it's arousal questionnaire co-primary, IIb ask actually X We the sexual study questions the of sensations was section about our the that a arousal. had of of IIb a as Phase endpoint. the specifically called in primary that as from

you blood to is which happens really about what to does Sildenafil feeling flow in what to So that questions the asked increased particular physical that get but are There when question things a highly be going a her tissue. area, also we general woman distress. is linked are

include diagnostic cases, genital indicates and also, sexual distress. in attain that, arousal the response female dysfunction maintain for men physical So also to rectal in of inability But those the that that criteria arousal respectively, and dysfunction both women, indications. causes disorder personal or

our Phase question had we IIb, in So a distress. about

exploratory what had of lots particular then questions IIb same feeling questions about We has being part about concern of and number orgasm about and about has and but we've total the endpoints, stressed So about -- guilt Phase a and other question inadequate in desire of questions we particular that a questions questionnaire different chose questions. XX the condition, distress. about

that So made part recommendation of is a the for data of outcomes. right? different what's disorder. Phase what phase reported called hierarchy, we our all is presented And Phase psychometric includes analysis we've This FDA these It's the to the III the validating IIb robust of to the the very patient relative a analysis. part of

sensations belongs multiple questions. improvements primary. saw in in desire. difficulty continue that, part in interpersonal in the improvements saw the what from of So the orgasm. saw distress scale. We obviously, improvements arousal the should really We other But be than we a to secondary. And in

an include have and a as collect of aspects to to like potential opportunity the we'd in our to So condition trial of include label possible. include and these as in the many other

to but each and is is for a exit clinically So statistical meaningful right improvement, those, FDA not just the a have established -- the matters II. to enough What from our we've now what what interviews Phase is improvement. It's woman. is of reviewing through that

what And right the at FDA so looking now. that's is

these there's we the Our what's saw that improvement, on been a III different if proposal for clinically our interested arousal possible. a and we're sensations where hierarchy. Phase study in And experience in those clearly including should all be sexual secondary primary, goes but our hierarchy, then into focus has aspects if of meaningful what

this. that sorry first a response very for did it is This generated also the little for So the go helps the but of ever that right, time but the go takes FDA clearly excited through, we're hopefully, about sponsor anything through outline to like We're why we brand new. why II, long all this. Phase all data in

Catherine Novack

helpful. That's No. Yes.

test Looking I'm hopefully that? the comparable curious, really Are what pause resuming you And technology. question more And say, or to, also this FDA IMPLANON just and looks forward one on like quarter. to Is feedback, for what that interesting trying DARE-LARCX. later That's clinical then looked it like let's at? to program NEXPLANON the dose? a just is the

Sabrina Johnson

a Yes, question. great that's

implant able level, through a have doses FDA to you've So and what your that. But relevant to out an it's sort establish demonstrated product do typically like have then to those and ultimate the yes, are on straight map releasing the you're like contraceptive much very look of work hormone that we've and into continue Phase move part of kind you to first do implant then looks part started right program your I, is, because hormones what at what question, contraceptive to right, -- hormones the going where started around to NEXPLANON, with of study. engagement you any like the obviously effectiveness the the of looks study you to effectiveness clinical that

you after keep So to go tend like duration products effectiveness. increments, in to of following years what right X-year, you similar is So first then a do X-year, the to like right? you X-year, and approval get your your those might women extending keep

going years. releasing products and very have to their analogous done as X NEXPLANON what with like So for the hormone well,

we've that so pause and it need to the of demonstrated the the that the that show of the -- that of component part definitely on-demand that Or regimen -- -- part open will piece, will already will terms with like from be that's but nonclinically, then sufficient Phase So I, be piece is be any be right, in a pause-resume, conversation this in FDA in to of what -- Phase of be as well? right? would vivo, that that demonstration piece III

Operator

remarks. concludes to closing would call for turn additional That I question-and-answer any Johnson to Sabrina session. Martucci back the over the or like

Sabrina Johnson

and do Thank you. comments. really I Well, have questions, great appreciate closing the I some

of by for identifying about First And provide and to our in ongoing of hear for of to use use to advancing for the frankly. to recent our stakeholders new enhanced time additional taking potential updates health, time. and everyone, it's therapies no that drive the doubt value building working an on momentum thanks, quite commitment incredible there's Daré all women. choices and all, women's outcomes XXXX, be the of

to be order is to executive research, we space and bipartisan the participation in as symptoms our increased White in attended menopause, we and an the additionally, training to given area for of Phase to about Ideation on Senate work us year, for to on the attention issues, focus a the for that including vaginal at while and various as in preparing particularly that and menopause, not the House stigmatized DARE-VVAX, our March, this overlooked and often thrilled $XXX of excited would and through monthly event continue recent ARPA initiatives DARE-HRTX million sexual relevant House call and We the is see awareness which, hormone-free our February well is authorize that health White vasomotor active mid-life our around public are was women's signing also menopause. the Phase underfunded and a we're that that specifically program candidate related bill boost of the II-ready potential unveiling it the today's a vaginal pain them therapy III. It's first

progress looking this new this arpa/inet.h, the of hub of Catalyst as by space we're the progress nationwide we and month, Investor in of the forward regional Hub, which selected menopause So bill. a member also ARPA-H. spoke the the to launched network innovation potential were seeing Earlier is health continued

access to award contracting priorities ARPA-H challenge on women's and help our areas really participation, funding health get remains innovation. input We forefront at for contracts. compared faster to can and that to traditional ensure flexible execution and potential provide government the we of Through

rest for of So investment these excited we're holds year to this can the moments for truly can boldly we're as show focus bringing today, the how you be that and Daré. much for and making we ecosystem And progress, entire accomplished women. what so just by innovate heard great

our including, with As for and we disorder, FDA expect looking forward giving and are our as look complete, where activities to several potential this pivotal to the the rest of Cream. discussions registration on single year, the Phase treatment and we're year, about, be our updates milestones III option study to as Ovaprene talking the sexual working commence Sildenafil we female arousal the we've been we to definitely the first-in-category study ahead for to expect update

support commercial Daré today. driving on milestones for keeping look also women And we we for and model innovation our you of we believe unique we're to all our of stakeholders. our value of our forward the So that, collaborators through the toward progress all updated positioned while accelerate well discussed to

thank So you.

Operator

for Ladies that you concludes joining. all today's and gentlemen, Thank call.

disconnect now may You

Daré Bioscience (DARE) 14 May 242024 Q1 Earnings call transcript